Table 3. Comparisons of clinical measures between 2000–2007 and 2008–2017.
| Characteristic | 2000–2007 (n=36) | 2008–2017 (n=111) | p value | ||
|---|---|---|---|---|---|
| Age | 0.763 | ||||
| Median age (yr) | 62 (52–69) | 62 (51–70) | |||
| FIGO stage | 0.175 | ||||
| IIIC | 25 (69.4) | 62 (55.9) | |||
| IV | 11 (30.6) | 49 (44.1) | |||
| Primary site | <0.001 | ||||
| Ovary | 32 (88.9) | 51 (45.9) | |||
| Fallopian tube | 1 (2.8) | 51 (45.9) | |||
| Peritoneum | 3 (8.3) | 9 (8.1) | |||
| Histology | 0.141 | ||||
| Serous carcinoma, high grade | 31 (86.1) | 99 (89.2) | |||
| Serous carcinoma, low grade | 0 (0.0) | 2 (1.8) | |||
| Clear cell carcinoma | 1 (2.8) | 4 (3.6) | |||
| Carcinosarcoma | 1 (2.8) | 3 (2.7) | |||
| Endometrioid carcinoma | 0 (0.0) | 2 (1.8) | |||
| Mucinous carcinoma | 2 (5.6) | 0 (0.0) | |||
| Poorly differentiated carcinoma | 0 (0.0) | 1 (0.9) | |||
| Mixed carcinoma | 1 (2.8) | 0 (0.0) | |||
| CA-125 (IU/mL) | |||||
| At exploratory laparotomy | 1,602 (740–3,316) | 1,240 (588–2,960) | 0.474 | ||
| At interval surgery | 19.2 (10.0–50.6) | 12 (8.8–21.9) | 0.012 | ||
| Bevacizumab | <0.001 | ||||
| Bevacizumab administration | 0 (0.0) | 64 (57.7) | |||
| Cycle | - | 21 (12–21) | |||
| Bevacizumab NOT administration | 36 (100.0) | 47 (42.3) | |||
| Surgical complexity score | 2 (2–4) | 13 (11–15) | <0.001 | ||
| Low (0–3) | 23 (63.9) | 1 (0.9) | <0.001 | ||
| Moderate (4–7) | 11 (30.6) | 6 (5.4) | |||
| High (8–18) | 2 (5.6) | 104 (93.7) | |||
| Surgical procedures during IDS | - | ||||
| Rectosigmoid colectomy | 10 (27.8) | 105 (94.6) | |||
| Vesicouterine peritonectomy | 0 (0) | 99 (89.2) | |||
| Greater omentectomy | 32 (88.9) | 82 (73.9) | |||
| Right diaphragm peritonectomy | 0 (0) | 105 (94.6) | |||
| Splenectomy | 0 (0) | 79 (71.2) | |||
| Lymphadenectomy | 9 (25.0) | 96 (86.5) | |||
| Completeness of resection (cm) | <0.001 | ||||
| 0 | 20 (55.6) | 104 (93.7) | |||
| ≥0.1 and ≤1 | 11 (30.6) | 5 (4.5) | |||
| >1 | 5 (13.9) | 2 (1.8) | |||
Values are presented as median (IQR) or number of patients (%).
FIGO, the International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery; IQR, interquartile range.